Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma

Bone Marrow Transplantation volume 41, pages 867–872 (2008)Cite this article

Abstract

The aim of this study was to identify risk factors associated with PFS in patients with Ewing sarcoma undergoing ASCT; 116 patients underwent ASCT in 1989–2000 and reported to the Center for International Blood and Marrow Transplant Research. Eighty patients (69%) received ASCT as first-line therapy and 36 (31%), for recurrent disease. Risk factors affecting ASCT were analyzed with use of the Cox regression method. Metastatic disease at diagnosis, recurrence prior to ASCT and performance score <90 were associated with higher rates of disease recurrence/progression. Five-year probabilities of PFS in patients with localized and metastatic disease at diagnosis who received ASCT as first-line therapy were 49% (95% CI 30–69) and 34% (95% CI 22–47) respectively. The 5-year probability of PFS in patients with localized disease at diagnosis, and received ASCT after recurrence was 14% (95% CI 3–30). PFS rates after ASCT are comparable to published rates in patients with similar disease characteristics treated with conventional chemotherapy, surgery and irradiation suggesting a limited role for ASCT in these patients. Therefore, ASCT if considered should be for high-risk patients in the setting of carefully controlled clinical trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Ginsberg JP, Woo SY, Johnson ME, Hicks MJ, Horowitz ME . Ewing's sarcoma family of tumors: Ewing's sarcoma of bone soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo and Poplack. Lippincott Williams and Wilkins: Philadelphia, PA, 2002, pp 973–1016.

    Google Scholar 

  2. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694–701.

    Article  CAS  PubMed  Google Scholar 

  3. Cangir A, Vietti TJ, Gehan EA, Burgert Jr EO, Thomas P, Tefft M et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887–893.

    Article  CAS  PubMed  Google Scholar 

  4. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide—A Children's Cancer Group and Pediatric Oncology Group Study. J Clin Oncol 2004; 22: 2873–2876.

    Article  CAS  PubMed  Google Scholar 

  5. Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044–3052.

    Article  CAS  PubMed  Google Scholar 

  6. Shankar AG, Ashley S, Craft AW, Pinkerton CR . Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003; 40: 141–147.

    Article  CAS  PubMed  Google Scholar 

  7. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979–1999. Cancer 2002; 94: 561–569.

    Article  PubMed  Google Scholar 

  8. Ahrens S, Hoffmann C, Jabar S, Braun-Munzinger G, Paulussen M, Dunst J et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999; 32: 186–195.

    Article  CAS  PubMed  Google Scholar 

  9. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80: 1020–1033.

    Article  CAS  PubMed  Google Scholar 

  10. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248–1255.

    Article  CAS  Google Scholar 

  11. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14: 1245–1251.

    Article  CAS  PubMed  Google Scholar 

  12. Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11: 1482–1488.

    Article  CAS  PubMed  Google Scholar 

  13. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS et al. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant 2006; 37: 175–181.

    Article  CAS  PubMed  Google Scholar 

  14. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J et al. Mega chemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 2005; 9: 618–621.

    Article  PubMed  Google Scholar 

  15. Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843–846.

    Article  CAS  PubMed  Google Scholar 

  16. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S et al. Impact of mega therapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697–705.

    CAS  PubMed  Google Scholar 

  17. Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 2001; 28: 1001–1011.

    Article  CAS  PubMed  Google Scholar 

  18. Kaplan E . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  19. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187.

    Google Scholar 

  20. Therneau T, Grambasch P . Modeling Survival Data: Extending the Cox Model. Springer Verlag: New York, NY, 2000.

    Book  Google Scholar 

  21. Andersen PK, Klein JP, Zhang MJ . Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med 1999; 18: 1489–1500.

    Article  CAS  PubMed  Google Scholar 

  22. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911–1918.

    Article  CAS  PubMed  Google Scholar 

  23. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812–2820.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Public Health Service Grant U24-CA76518 from the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung and Blood Institute; Office of Naval Research; Health Services Research Administration (DHHS); and grants from AABB; Abbott Laboratories; Aetna; American International Group Inc.; Amgen Inc.; Anonymous donation to the Medical College of Wisconsin; AnorMED Inc.; Astellas Pharma US Inc.; Baxter International Inc.; Berlex Laboratories Inc.; Biogen IDEC Inc.; BioOne Corporation; Blood Center of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Bristol-Myers Squibb Company; Cangene Corporation; Celgene Corporation; CellGenix GmbH; Cerus Corporation; Cylex Inc.; CytoTherm; DOR BioPharma Inc.; Dynal Biotech, an Invitrogen Company; EKR Therapeutics; Enzon Pharmaceuticals Inc.; Gambro BCT Inc.; Gamida Cell Ltd.; Genzyme Corporation; Gift of Life Bone Marrow Foundation; GlaxoSmithKline Inc.; Histogenetics Inc.; HKS Medical Information Systems; Hospira Inc.; Kiadis Pharma; Kirin Brewery Co., Ltd.; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec Inc.; MultiPlan Inc.; National Marrow Donor Program; Nature Publishing Group; Oncology Nursing Society; Osiris Therapeutics Inc.; Pall Life Sciences; PDL BioPharma Inc.; Pfizer Inc.; Pharmion Corporation; Roche Laboratories; Sanofi-aventis; Schering Plough Corporation; StemCyte Inc.; StemSoft Software Inc.; SuperGen Inc.; Sysmex; Teva Pharmaceutical Industries; The Marrow Foundation; THERAKOS Inc.; University of Colorado Cord Blood Bank; ViaCell Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma Inc.; Wellpoint Inc.; and Zelos Therapeutics Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, or any other agency of the US Government.

Author information

Authors and Affiliations

  1. Department of Pediatric Oncology, New York University, New York, NY, USA

    S L Gardner

  2. Statistical Center, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

    J Carreras & M Eapen

  3. Department of Statistics & Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada

    C Boudreau

  4. Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA

    B M Camitta

  5. BMT Internal Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA

    R H Adams

  6. Department of Pediatric Oncology, John Hopkins Hospital, Baltimore, MD, USA

    A R Chen

  7. Department of Bone Marrow Transplantation, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

    S M Davies

  8. Department of Bone Marrow Transplantation, Florida Hospital Cancer Institute, Orlando, FL, USA

    J R Edwards

  9. Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA

    A C Grovas

  10. Department of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN, USA

    G A Hale

  11. Department of Hematology/Oncology, University Hospitals of Cleveland, Cleveland, OH, USA

    H M Lazarus

  12. Department of Hematology/Oncology, University of Minnesota, Minneapolis, MN, USA

    M Arora

  13. Department of Bone Marrow Transplantation, Loyola University Medical Center, Maywood, IL, USA

    P J Stiff

Authors
  1. S L Gardner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Boudreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B M Camitta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R H Adams
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A R Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S M Davies
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J R Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A C Grovas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. G A Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. P J Stiff
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Eapen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Eapen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gardner, S., Carreras, J., Boudreau, C. et al. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant 41, 867–872 (2008). https://doi.org/10.1038/bmt.2008.2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.2

Keywords

This article is cited by

Search

Advanced search

Quick links